GLP-1 (SMA) 30mg

GLP-1 (SMA) is a synthetic analogue of the naturally occurring Glucagon-Like Peptide-1 (GLP-1). It is known for its ability to regulate blood sugar levels by enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Research has indicated that GLP-1 (SMA) may contribute to improved cardiovascular, liver, and metabolic health. Additionally, it has been found to reduce appetite by delaying gastric emptying and lowering intestinal motility, which can aid in weight management. Beyond its effects on glucose metabolism and appetite control, GLP-1 (SMA) has shown potential benefits in reducing the risk of major cardiovascular events such as heart attacks and strokes, particularly in individuals with type 2 diabetes. Studies suggest it may also support liver health by reducing fat accumulation in the liver, which could be beneficial for those with non-alcoholic fatty liver disease (NAFLD

Overview

GLP-1 (SMA) is a glucagon-like peptide-1 (GLP-1) receptor agonist that plays a crucial role in managing blood sugar levels, weight regulation, and cardiovascular health. Originally developed as a treatment for type 2 diabetes, GLP-1 (SMA) has gained significant attention for its additional benefits, including weight loss and potential neuroprotective effects.

Mechanism of Action

GLP-1 (SMA) mimics the natural GLP-1 hormone, which is secreted by the intestines in response to food intake. This hormone stimulates insulin secretion while suppressing glucagon release, thereby lowering blood glucose levels. Additionally, GLP-1 (SMA) slows gastric emptying, leading to prolonged satiety and reduced appetite, which contributes to weight loss. Following is step by step explanation of its mechanism of action.  

1. GLP-1 Receptor Activation

GLP-1 (SMA) binds to and activates the GLP-1 receptor, a G-protein-coupled receptor (GPCR) found on:

• Pancreatic beta cells
• Hypothalamic neurons
• Gastrointestinal tract
• Heart and other peripheral tissues

2. Enhanced Insulin Secretion (Glucose-dependent)

Upon receptor activation, GLP-1 (SMA) increases cyclic AMP (cAMP) levels in pancreatic β-cells, leading to:

• Enhanced insulin secretion, but only when blood glucose levels are elevated
• Reduced risk of hypoglycemia compared to insulin or sulfonylureas

3. Suppression of Glucagon Secretion

GLP-1 (SMA) inhibits glucagon release from pancreatic α-cells, especially when blood glucose is high. This reduces hepatic glucose production, contributing to lower blood glucose levels.

4. Delayed Gastric Emptying

It slows down gastric emptying, which:

• Reduces postprandial glucose spikes
• Enhances satiety

5. Central Appetite Suppression

GLP-1 (SMA) acts on GLP-1 receptors in the hypothalamus, particularly the arcuate nucleus, to:

• Reduce appetite
• Decrease caloric intake This is a major mechanism in its effectiveness for weight loss.

Here is summary of key actions.

Target	Effect

 

Pancreatic β-cells

↑ Glucose-dependent insulin secretion

 

Pancreatic α-cells

↓ Glucagon secretion

 

GI Tract

↓ Gastric emptying

 

Brain

↓ Appetite, ↑ Satiety

 

Liver (indirect)

↓ Glucose production

 

GLP-1 (SMA) structutre

  Amino Acid Sequence: HXEGTFTSDV SSYLEGQAAK EFIAWLVRGR Molecular Formula: C₁₈₇H₂₉₁N₄₅O₅₉​Molecular Weight: Approximately 4,113.58 g/mol​PubChem Compound ID (CID): 56843331​ CAS (Chemical Abstracts Service) Number: 910463-68-2​ Synonyms: Ozempic,​ Rybelsus,  NNC 0113-0217,​ NN9535​, Sermaglutide​,  

Research

1. Blood Sugar Control

GLP-1 (SMA) is widely used for the treatment of type 2 diabetes mellitus. By enhancing insulin secretion and reducing glucagon levels, it helps maintain stable blood sugar levels, reducing the risk of hyperglycemia. Clinical studies have demonstrated its efficacy in lowering HbA1c, a key marker of long-term blood glucose control. Additionally, GLP-1 (SMA) slows gastric emptying, which helps reduce postprandial glucose spikes and promotes satiety, contributing to better overall glycemic management. Beyond its glucose-lowering effects, it has been shown to support weight loss, which is particularly beneficial for individuals with obesity-related insulin resistance. Studies have also suggested potential cardiovascular benefits, including a reduced risk of major adverse cardiovascular events such as heart attack and stroke, making GLP-1 (SMA) an important therapeutic option for patients with type 2 diabetes at high cardiovascular risk. (1)

2. Weight management

In addition to its glucose-lowering effects, GLP-1 (SMA) is also approved for chronic weight management. By reducing appetite and promoting satiety, it has shown substantial weight loss results in individuals with obesity or overweight conditions. This makes it a popular choice among patients looking for non-surgical weight loss interventions. GLP-1 (SMA) works by mimicking the GLP-1 hormone, which regulates hunger and food intake by acting on appetite-control centers in the brain, particularly the hypothalamus. Clinical trials, such as the STEP (GLP-1 (SMA) Treatment Effect in People with Obesity) studies, have demonstrated significant weight reduction, with some patients losing over 10-15% of their body weight. Additionally, GLP-1 (SMA) has been associated with improvements in metabolic health markers, including reductions in waist circumference, blood pressure, and lipid levels, further enhancing its benefits for individuals with obesity-related health risks. Its once-weekly injection format also offers convenience, improving patient adherence compared to daily weight-loss medications. (2)

3. Cardiovascular Benefits

Research indicates that GLP-1 (SMA) provides cardiovascular protection by reducing the risk of major adverse cardiac events such as heart attack and stroke. It has been shown to lower blood pressure, reduce inflammation, and improve lipid profiles, making it beneficial for individuals with diabetes and heart disease.(3)

4. Potential Neuroprotective Effects:

GLP-1 (SMA), a GLP-1 receptor agonist, has shown potential neuroceptive effects by modulating brain regions involved in stress, mood, and autonomic regulation. Research indicates that GLP-1 receptors in the amygdala, hypothalamus, and brainstem play a role in reducing neuroinflammation and enhancing neuronal resilience, which may help regulate stress responses and anxiety. Additionally, GLP-1 (SMA) interacts with the autonomic nervous system, influencing parasympathetic activity and promoting a greater sense of calm. Studies also suggest antidepressant-like properties, likely due to its impact on neurotransmitter pathways, including dopamine and serotonin, as well as its ability to reduce inflammation, a factor often linked to depression. Furthermore, GLP-1 (SMA) has demonstrated neuroprotective benefits in models of Alzheimer’s disease by enhancing autophagy and preventing neuronal loss, indicating potential cognitive benefits. (5) Beyond mood and stress regulation, GLP-1 (SMA) influences reward and motivation pathways, altering food preferences and intake by interacting with neural circuits responsible for appetite and reward processing. Clinical studies in rodents have shown activation in the lateral parabrachial nucleus, which regulates food motivation and energy balance. While some patients report improved mood and reduced compulsive behaviors, others have experienced side effects such as dizziness and depressive symptoms, highlighting the need for further investigation. These findings suggest that GLP-1 (SMA) effects extend beyond metabolic regulation to broader neuroceptive and neuropsychiatric domains, warranting more research into its therapeutic potential for neurological and psychiatric disorders.

5- Chronic Kidney Disease:

In adults with type 2 diabetes and chronic kidney disease, GLP-1 (SMA) has been utilized to reduce the risk of kidney function decline, kidney failure, and cardiovascular death. Studies suggest that GLP-1 (SMA) renal protective effects may stem from its ability to lower blood pressure, reduce inflammation, and improve glycemic control, all of which contribute to slowing the progression of kidney disease. Additionally, GLP-1 (SMA) has been associated with a decrease in albuminuria, a key marker of kidney damage, which further supports its role in protecting renal function. Clinical trials, such as the FLOW study, are currently investigating its long-term benefits in patients with kidney diabetic disease. Moreover, its cardiovascular benefits, including a reduced risk of heart failure and major adverse cardiovascular events (MACE), make it an essential therapeutic option for individuals at high risk of both renal and cardiovascular complications. (4)

Product usage

This product is strictly designated as a research chemical and is intended solely for in vitro testing and laboratory experimentation. It is not approved for human or animal consumption under any circumstances. All information provided on this website is for educational and scientific research purposes only. Any bodily introduction, including ingestion, injection, or topical application, is strictly prohibited by law. This product should only be handled by licensed and qualified professionals in controlled laboratory settings. It is neither a drug, food, nor cosmetic and must not be misbranded, misused, or mislabeled as such. Improper handling, distribution, or use of this product may result in legal consequences. Always follow all relevant safety protocols, regulations, and ethical guidelines when working with this material.

References

https://www.drugs.com/semaglutide.html?utm_ https://en.wikipedia.org/wiki/Semaglutide https://www.nature.com/articles/s41591-024-02996-7? Drugs.com+1WebMD+1 https://pmc.ncbi.nlm.nih.gov/articles/PMC7213778/?utm_ https://neuro-sens.com/cns-effects-of-wegovy-semaglutide/

How GLP-1 (SMA) Works for Weight Loss GLP-1 (SMA) promotes weight loss by: Reducing Appetite: It slows down the movement of food through the stomach (gastric emptying) and helps regulate the hunger centers in the brain, leading to a feeling of fullness and reducing cravings. Improving Insulin Sensitivity: GLP-1 (SMA) helps manage blood sugar levels by stimulating insulin release when glucose levels are elevated. Decreasing Caloric Intake: Because it reduces hunger, patients often consume fewer calories, leading to gradual and sustained weight loss.

Drucker D. J. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001 Wilding, J., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 384(11), 989. https://doi.org/10.1056/NEJMoa2032183 Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., Wilding, J., &Rubino, D. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring, Md.), 28(6), 1050–1061. https://doi.org/10.1002/oby.22794 Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., &Kiortsis, D. N. (2019). Glp-1 (SMA) as a promising antiobesity drug. Obesity reviews : an official journal of the International Association for the Study of Obesity, 20(6), 805–815. https://doi.org/10.1111/obr.12839 Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators (2021). Effect of Continued Weekly Subcutaneous Semaglutidevs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224